Moderna Stock Doubles on Merck Melanoma Vaccine Results
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Moderna stock more than doubled after the company reported its Merck-partnered melanoma cancer vaccine cuts recurrence in a large trial (CNBC, Reuters)
- Merck partnered with Moderna on the cancer vaccine, which showed promise in a late-stage trial (CNBC)
- The melanoma vaccine specifically demonstrated a reduction in recurrence rather than a front-line treatment effect (Reuters)
- Moderna shares surged on the news, according to Reuters' coverage of the trial readout
Why it matters: Moderna's stock more than doubling in a single session on a late-stage cancer vaccine readout is a rare biotech event — the Merck-partnered melanoma therapy demonstrated it cuts recurrence in a large trial, per CNBC and Reuters, reframing the company beyond its COVID vaccine revenue base.
Ask SkimNews
